Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPD489 (Lisdexamfetamine) Augmentation in MDD
NCT01436162Phase 3Completed
- Sponsor
- Takeda
- Start
- Oct 2011
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of lisdexamfetamine in major depressive disorder (MDD), sponsored by Takeda. Started Oct 2011; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01436162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01436162.